Axecap Investments LLC Invests $2.10 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Axecap Investments LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,994 shares of the biopharmaceutical company’s stock, valued at approximately $2,096,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares during the period. TD Asset Management Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after purchasing an additional 166,998 shares during the last quarter. Swedbank AB bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $129,257,000. Finally, Epoch Investment Partners Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $99,667,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on REGN shares. JPMorgan Chase & Co. increased their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,102.19.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $941.39 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The firm has a market capitalization of $103.73 billion, a P/E ratio of 27.81, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12. The company’s 50-day moving average is $1,098.29 and its 200 day moving average is $1,040.67.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company posted $8.79 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.